{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T15:03:04Z","timestamp":1761490984364},"reference-count":18,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Thorax"],"accepted":{"date-parts":[[2020,2,12]]},"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:p>The British Thoracic Society (BTS) guideline on the use of long-term macrolides in adults with respiratory disease has been published. It indicates where there is evidence to support the use of long-term low-dose macrolides and where there is not. It discusses the potential benefits of such therapy for patients and also describes the potential risks to individuals and wider populations. It seeks to provide a pragmatic approach for clinicians considering long-term macrolide therapy for their patients. This guideline has also acted as a learning exercise for the BTS in introducing the Grading of Recommendations Assessment, Development and Evaluation approach to guideline development, which will be used going forwards.<\/jats:p>","DOI":"10.1136\/thoraxjnl-2019-214039","type":"journal-article","created":{"date-parts":[[2020,4,17]],"date-time":"2020-04-17T17:41:58Z","timestamp":1587145318000},"page":"405-406","update-policy":"http:\/\/dx.doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["BTS guideline on long-term macrolides in adults with respiratory disease: not quite a panacea"],"prefix":"10.1136","volume":"75","author":[{"given":"David","family":"Smith","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2020,4,17]]},"reference":[{"key":"2024092103350752000_75.5.405.1","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2019-213929"},{"key":"2024092103350752000_75.5.405.2","first-page":"632","article-title":"[Clinical effects of low-dose long-term erythromycin chemotherapy on diffuse panbronchiolitis]","volume":"25","author":"Kudoh","year":"1987","journal-title":"Nihon Kyobu Shikkan Gakkai Zasshi"},{"key":"2024092103350752000_75.5.405.3","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00078-09"},{"key":"2024092103350752000_75.5.405.4","doi-asserted-by":"publisher","DOI":"10.1159\/000320320"},{"key":"2024092103350752000_75.5.405.5","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S2213-2600(13)70038-9","article-title":"Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases","volume":"1","author":"Serisier","year":"2013","journal-title":"Lancet Respir Med"},{"key":"2024092103350752000_75.5.405.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60953-2"},{"key":"2024092103350752000_75.5.405.7","unstructured":"Altenburg JDG C , Van Der Werf T , Boersma W . Long term azithromycin treatment: a randomised placebo-controlled trial in non-CF bronchiectasis; results from the bat trial. European Respiratory J Conference 2011;38."},{"key":"2024092103350752000_75.5.405.8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.2290"},{"key":"2024092103350752000_75.5.405.9","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2012-202698"},{"key":"2024092103350752000_75.5.405.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31281-3"},{"key":"2024092103350752000_75.5.405.11","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00107514"},{"key":"2024092103350752000_75.5.405.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2015.07.032"},{"key":"2024092103350752000_75.5.405.13","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-015-2480-0"},{"key":"2024092103350752000_75.5.405.14","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02067-13"},{"key":"2024092103350752000_75.5.405.15","unstructured":"Emergency Preparedness and Health Protection Policy Directorate, HM Government . Contained and controlled: the UK\u2019s 20-year vision for antimicrobial resistance 2019."},{"key":"2024092103350752000_75.5.405.16","unstructured":"WHO . Global antimicrobial resistance surveillance system (glass) report: early implementation 2017-2018 2018."},{"key":"2024092103350752000_75.5.405.17","unstructured":"WHO . The selection and use of essential medicines: report of the 21st WHO Expert Committee on the selection and use of essential medicines. Geneva: WHO, 2017."},{"key":"2024092103350752000_75.5.405.18","unstructured":"GMC . Ethical guidance for doctors London: GMC, 2019. Available: https:\/\/www.gmc-uk.org\/ethical-guidance\/ethical-guidance-for-doctors#prescribing"}],"container-title":["Thorax"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/thoraxjnl-2019-214039","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T10:35:25Z","timestamp":1726914925000},"score":1,"resource":{"primary":{"URL":"https:\/\/thorax.bmj.com\/lookup\/doi\/10.1136\/thoraxjnl-2019-214039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,17]]},"references-count":18,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,4,23]]},"published-print":{"date-parts":[[2020,5]]}},"alternative-id":["10.1136\/thoraxjnl-2019-214039"],"URL":"https:\/\/doi.org\/10.1136\/thoraxjnl-2019-214039","relation":{},"ISSN":["0040-6376","1468-3296"],"issn-type":[{"type":"print","value":"0040-6376"},{"type":"electronic","value":"1468-3296"}],"subject":[],"published":{"date-parts":[[2020,4,17]]}}}